Immunovant Cash and Cash Equivalents Reach $994.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy IMVT?
As of December 31, 2025, Immunovant's cash and cash equivalents totaled $994.5 million, providing runway for announced indications through the potential commercial launch of IMVT-1402 in GD
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMVT
Wall Street analysts forecast IMVT stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.410
Low
22.00
Averages
37.00
High
54.00
Current: 24.410
Low
22.00
Averages
37.00
High
54.00
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Logos Global Management Increases Immunovant Stake to 1.375 Million Shares
- Significant Stake Increase: Logos Global Management LP disclosed an increase of 1,100,000 shares in Immunovant during Q4 2025, with an estimated transaction value of $24.5 million, indicating strong confidence in the company's clinical trial progress.
- Value Growth of Holdings: This acquisition brings Logos' total holdings in Immunovant to 1,375,000 shares, valued at approximately $34.95 million, representing 2.11% of its assets under management, highlighting the fund's focus on the biotech sector.
- Strong Market Performance: As of March 13, 2026, Immunovant shares were priced at $24.72, reflecting a 29.3% increase over the past year, outperforming the S&P 500 by 10.58%, showcasing its competitive edge and investment appeal.
- Clinical Trial Developments: Immunovant's lead candidate, batoclimab, has completed Phase III trials for myasthenia gravis and is currently in Phase III trials for thyroid eye disease, with results expected in the first half of 2026, which will significantly impact its regulatory path.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
S&P 500 Futures Rise in Pre-Market Session; Adobe and Ulta Beauty Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Klarna Group Performance: Klarna Group PLC (KLAR) saw a 6.4% increase in pre-market trading.
Legence Corp Performance: Legence Corp. (LGN) experienced a 4.4% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment ahead of the market opening.
See More
Alpine Global Management Reduces Immunovant Holdings
- Share Reduction Details: On February 17, 2026, Alpine Global Management disclosed a sale of 127,039 shares of Immunovant, valued at approximately $2.83 million, indicating a potential shift in confidence, although Immunovant still represents 11.4% of its 13F AUM.
- Valuation Impact: The sale resulted in a $22.36 million decrease in Immunovant's quarter-end valuation, highlighting the effects of market price fluctuations and trading activities on the fund's asset burden, which may influence investor expectations for future performance.
- Company Overview: Immunovant focuses on developing monoclonal antibody therapies for autoimmune diseases, with a market capitalization of $5.35 billion and a negative net income of $464.20 million; however, its lead asset, batoclimab, could achieve commercialization if clinical trials succeed, addressing significant market needs.
- Investor Outlook: Despite the reduction, Alpine maintains a significant investment in Immunovant, reflecting confidence in the company's future clinical milestones, with topline data from two Phase 3 studies for batoclimab expected in the first half of this year, potentially presenting new growth opportunities for investors.
See More
S&P 500 Futures Rise in Pre-Market Trading; Circle Internet Group and Axon Enterprise Take the Lead
Stock Market Opening: U.S. stock markets are set to open in two hours.
Circle Internet Group Inc. Performance: Circle Internet Group Inc. (CRCL) saw a 17.0% increase in pre-market trading.
Axon Enterprise Inc. Performance: Axon Enterprise Inc. (AXON) experienced a 15.0% rise in pre-market trading.
Market Sentiment: The significant pre-market gains for both companies indicate positive investor sentiment ahead of the market opening.
See More
Purcell & Lefkowitz Investigates Immunovant for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Immunovant, Inc. to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation particularly emphasizes shareholder rights, with the law firm offering free consultations to encourage shareholders to understand their rights and options, demonstrating a commitment to protecting investor interests.
- Legal Service Commitment: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide who are victims of securities fraud and breaches of fiduciary duty, highlighting its expertise in the legal services sector.
- Information Access Channels: Shareholders can obtain more information by visiting the law firm's website or directly contacting attorneys, ensuring transparency and timely communication to enhance shareholder confidence in corporate governance.
See More
Logos Global Management Increases Immunovant Stake to 1.375 Million Shares
- Significant Stake Increase: Logos Global Management LP disclosed an increase of 1,100,000 shares in Immunovant during Q4 2025, with an estimated transaction value of $24.5 million, indicating strong confidence in the company's clinical trial progress.
- Value Growth of Holdings: This acquisition brings Logos' total holdings in Immunovant to 1,375,000 shares, valued at approximately $34.95 million, representing 2.11% of its assets under management, highlighting the fund's focus on the biotech sector.
- Strong Market Performance: As of March 13, 2026, Immunovant shares were priced at $24.72, reflecting a 29.3% increase over the past year, outperforming the S&P 500 by 10.58%, showcasing its competitive edge and investment appeal.
- Clinical Trial Developments: Immunovant's lead candidate, batoclimab, has completed Phase III trials for myasthenia gravis and is currently in Phase III trials for thyroid eye disease, with results expected in the first half of 2026, which will significantly impact its regulatory path.
See More
Logos Increases Immunovant Stake to $35 Million
- Significant Stake Increase: Logos Global Management LP purchased an additional 1.1 million shares of Immunovant in Q4 2025, with an estimated transaction value of $24.5 million, reflecting strong confidence in the company's potential.
- Value Growth: By the end of the quarter, Logos' total stake in Immunovant rose to approximately $35 million, indicating a substantial increase driven by both new shares and price appreciation, highlighting its importance in the fund's portfolio.
- Portfolio Allocation Shift: The stake in Immunovant increased from 0.4% to about 2%, which, while not placing it in the top five holdings, signifies a meaningful commitment within a concentrated portfolio, showcasing Logos' focus on the biotech sector.
- Clinical Progress Monitoring: Immunovant is advancing batoclimab across multiple autoimmune indications, with key Phase 3 study results expected in the first half of 2026, which will significantly impact its regulatory trajectory.
See More
S&P 500 Futures Rise in Pre-Market Session; Adobe and Ulta Beauty Underperform
Market Opening: U.S. stock markets are set to open in two hours.
Klarna Group Performance: Klarna Group PLC (KLAR) saw a 6.4% increase in pre-market trading.
Legence Corp Performance: Legence Corp. (LGN) experienced a 4.4% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate a positive sentiment ahead of the market opening.
See More
Alpine Global Management Reduces Immunovant Holdings
- Share Reduction Details: On February 17, 2026, Alpine Global Management disclosed a sale of 127,039 shares of Immunovant, valued at approximately $2.83 million, indicating a potential shift in confidence, although Immunovant still represents 11.4% of its 13F AUM.
- Valuation Impact: The sale resulted in a $22.36 million decrease in Immunovant's quarter-end valuation, highlighting the effects of market price fluctuations and trading activities on the fund's asset burden, which may influence investor expectations for future performance.
- Company Overview: Immunovant focuses on developing monoclonal antibody therapies for autoimmune diseases, with a market capitalization of $5.35 billion and a negative net income of $464.20 million; however, its lead asset, batoclimab, could achieve commercialization if clinical trials succeed, addressing significant market needs.
- Investor Outlook: Despite the reduction, Alpine maintains a significant investment in Immunovant, reflecting confidence in the company's future clinical milestones, with topline data from two Phase 3 studies for batoclimab expected in the first half of this year, potentially presenting new growth opportunities for investors.
See More
S&P 500 Futures Rise in Pre-Market Trading; Circle Internet Group and Axon Enterprise Take the Lead
Stock Market Opening: U.S. stock markets are set to open in two hours.
Circle Internet Group Inc. Performance: Circle Internet Group Inc. (CRCL) saw a 17.0% increase in pre-market trading.
Axon Enterprise Inc. Performance: Axon Enterprise Inc. (AXON) experienced a 15.0% rise in pre-market trading.
Market Sentiment: The significant pre-market gains for both companies indicate positive investor sentiment ahead of the market opening.
See More
Purcell & Lefkowitz Investigates Immunovant for Potential Fiduciary Breaches
- Investigation Launched: Purcell & Lefkowitz LLP has announced an investigation into Immunovant, Inc. to determine whether the company's directors breached their fiduciary duties in recent corporate actions, potentially impacting shareholder interests.
- Shareholder Rights Focus: The investigation particularly emphasizes shareholder rights, with the law firm offering free consultations to encourage shareholders to understand their rights and options, demonstrating a commitment to protecting investor interests.
- Legal Service Commitment: Purcell & Lefkowitz LLP is dedicated to representing shareholders nationwide who are victims of securities fraud and breaches of fiduciary duty, highlighting its expertise in the legal services sector.
- Information Access Channels: Shareholders can obtain more information by visiting the law firm's website or directly contacting attorneys, ensuring transparency and timely communication to enhance shareholder confidence in corporate governance.
See More
